Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands joint study group for ovarian cancer |
| |
| Affiliation: | 1. Integrated Cancer Research Center, School of Biological Sciences, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, GA 30332, USA;2. Department of Obstetrics and Gynecology, University of North Carolina, 3009 Old Clinic Building, Chapel Hill, NC 27599, USA;3. Ovarian Cancer Institute, 1266 W. Paces Ferry Rd NW #339, Atlanta, GA 30327, USA;4. Center for the Study of Systems Biology, School of Biological Sciences, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, GA 30332, USA |
| |
| Abstract: | ![]()
In 23 evaluable patients with advanced ovarian epithelial cancer refractory to combination therapy with cisplatin and an alkylating agent, teniposide (VM-26) was administered as a short-term i.v. infusion at a dose of 100 mg/m2 on days 1 and 2, every 3 weeks. Toxocity was moderate and comparable to the pattern known from other studies. No objective response has been observed, showing that teniposide is not active as second-line therapy in this disease. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
